Please assess the completion status of the following clinical trial:

Trial Title: Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary myelofibrosis, essential thrombocythemia related myelofibrosis, or polycythemia vera related myelofibrosis requiring therapy, including:~  * Those previously treated and relapsed or refractory~ * Or, if newly diagnosed, with intermediate or high risk according to Lille scoring system (adverse prognostic factors are: hemoglobin \[Hb\] \< 10 g/dl, white blood cell count \[WBC\] \< 4 or \> 30 x 10\^9/L; risk group: 0 = low, 1 = intermediate, 2 = high)~ * Or with symptomatic splenomegaly (must be \>= 23 cm by ultrasound in the longitudinal axis)~* Signed informed consent: patients must have signed consents for both the arsenic trioxide with ascorbic acid protocol and for the hematologic malignancy procurement protocol to be eligible to participate~* Patients must have been off any primary myelofibrosis (PMF)-directed experimental therapy for 4 weeks prior to entering this study and have recovered from the toxic effects (grade 0-1) of that therapy; treatment with hydroxyurea and erythropoietin are permitted until study initiation~* Serum bilirubin levels =\< 2 times the upper limit of the normal range for the laboratory (ULN); higher levels are acceptable if these can be attributed by treating physician to active hemolysis or ineffective erythropoiesis due to myelofibrosis~* Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) levels =\< 2 x ULN~* Serum creatinine levels =\< 1.5 x ULN~* Women of childbearing potential must have a negative serum or urine pregnancy test prior to arsenic trioxide treatment and should be advised to avoid becoming pregnant~* Men must be advised to not father a child while receiving treatment with arsenic trioxide~* Both women of childbearing potential and men must practice effective methods of contraception (those generally accepted as standard of care measures)~* Women of childbearing potential are women who are not menopausal for 12 months or who have not undergone previous surgical sterilization~* If the subject is a woman of childbearing potential, she must use a medically acceptable form of contraception during the study period and for 30 days thereafter~* If the subject is a man he must be surgically sterile or must use a medically approved method of contraception for the duration of the study and for 60 days following the last dose of arsenic trioxide~Exclusion Criteria:~* Nursing and pregnant females; should a woman become pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately~* New York Heart Association (NYHA) grade II or greater congestive heart failure~* Unstable angina~* Corrected QT interval (QTc) \> 450 in the presence of potassium \>= 4 mEq/L and magnesium \>= 1.7 mEq/L~* Eastern Cooperative Oncology Group (ECOG) \> 2~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days, or anticipation of the need for major surgical procedure during the course of the study~* Biopsy or other minor surgical procedure, excluding placement of a vascular access device or bone marrow biopsy, within 7 days prior to study enrollment~* Ongoing serious, non-healing wound, ulcer, or bone fracture~* Known hypersensitivity to any component of arsenic trioxide

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (arsenic trioxide with or without ascorbic acid) (Type: EXPERIMENTAL): Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).